1. Home
  2. VNRX vs VTGN Comparison

VNRX vs VTGN Comparison

Compare VNRX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.44

Market Cap

24.5M

Sector

Health Care

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNRX
VTGN
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
25.3M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
VNRX
VTGN
Price
$0.44
$0.24
Analyst Decision
Strong Buy
Hold
Analyst Count
5
3
Target Price
$1.67
$0.90
AVG Volume (30 Days)
626.8K
2.9M
Earning Date
05-12-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
$1,727,384.00
N/A
Revenue This Year
$355.66
$124.49
Revenue Next Year
$849.08
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
40.04
N/A
52 Week Low
$0.13
$0.20
52 Week High
$3.26
$5.14

Technical Indicators

Market Signals
Indicator
VNRX
VTGN
Relative Strength Index (RSI) 19.99 38.43
Support Level $0.18 $0.21
Resistance Level $0.91 $0.66
Average True Range (ATR) 0.09 0.02
MACD -0.01 0.01
Stochastic Oscillator 1.72 11.49

Price Performance

Historical Comparison
VNRX
VTGN

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: